DESCRIPTION: (Adapted from the Investigator's Abstract) Chemical
Intolerance (CI) in humans is defined as the inability to tolerate
environmental chemicals due to experience of symptoms associated with those
chemicals. Although CI is prevalent in individuals claiming that prior
chemical exposures produced their intolerance, the underlying etiology
remains unknown. A high percentage of individuals reporting CI present with
psychiatric symptomatology, and some investigators have suggested that CI is
an atypical form of posttraumatic stress disorder (PTSD). The proposed work
emphasizes the parallels between PTSD and CI in the development of a
potential animal model for CI. Animal models of four phenomena appear most
suitable for examining PTSD and, therefore, CI: 1) sensitization of the
central nervous system (CNS), 2) conditioned fear, 3) extinction of a
conditioned fear response and 4) avoidance of a conditioned stimulus. In
support of CI as a PTSD-like phenomenon, recent studies in this laboratory
have found that rats given repeated daily inhalation of low levels of
formaldehyde (Form) demonstrated long-term cross-sensitization to
cocaine-induced locomotion. In addition, daily Form treated rats exhibited
increased avoidance to subsequent Form, and a reduced ability to extinguish
a conditioned fear response to an odor paired with foot shock. Since Form
does not penetrate beyond the upper airway, it is likely that Form serves as
a stressor to produce sensitization. For the proposed studies, four
exposure doses of Form will be employed. The first specific aim will test
the hypothesis that repeated Form exposure produces increases in
stress/anxiety responses after subsequent Form presentation in the same or
different environment from which original exposures occurred. Serum
corticosterone levels and behaviors reflective of anxiety/stress will be
monitored during and after re-exposure to Form. The second specific aim
will examine the hypothesis that repeated Form induces sensitization to
later Form presentation and cross-sensitization to cocaine via the
hypothalamic-pituitary-adrenal (HPA) axis. Cross-sensitivity to cocaine
will be monitored behaviorally, and nucleus accumbens dopamine levels will
be measured by in vivo microdialysis. Form sensitization to itself will be
measured by assessment of nucleus accumbens dopamine levels and also
behaviorally by monitoring avoidance responses to later Form presentation.
This aim will also perform adrenalectomy in one-half of rats to determine
whether an intact HPA axis is required for Form-induced effects. The third
specific aim will test the hypothesis that repeated Form exposure produces a
decreased ability to extinguish a conditioned fear response. The
specificity of the effect (context vs odor or tone) will also be explored.
The study of behavioral and neurochemical sensitization, conditioned fear
and extinction in Form-exposed rodents will provide a mechanistically-based
animal model system for studying the development and maintenance of CI in
humans.
National Institute of Environmental Health Sciences
CFDA Code
113
DUNS Number
041485301
UEI
XRJSGX384TD6
Project Start Date
01-September-1998
Project End Date
31-August-2001
Budget Start Date
01-September-1998
Budget End Date
31-August-1999
Project Funding Information for 1998
Total Funding
$164,885
Direct Costs
$118,431
Indirect Costs
$46,454
Year
Funding IC
FY Total Cost by IC
1998
National Institute of Environmental Health Sciences
$164,885
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01ES009135-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01ES009135-01A1
Patents
No Patents information available for 1R01ES009135-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01ES009135-01A1
Clinical Studies
No Clinical Studies information available for 1R01ES009135-01A1
News and More
Related News Releases
No news release information available for 1R01ES009135-01A1
History
No Historical information available for 1R01ES009135-01A1
Similar Projects
No Similar Projects information available for 1R01ES009135-01A1